HRP20240226T1 - Pripravci cjepiva koji sadrže protein vezivanja mutiranog faktora h - Google Patents

Pripravci cjepiva koji sadrže protein vezivanja mutiranog faktora h Download PDF

Info

Publication number
HRP20240226T1
HRP20240226T1 HRP20240226TT HRP20240226T HRP20240226T1 HR P20240226 T1 HRP20240226 T1 HR P20240226T1 HR P20240226T T HRP20240226T T HR P20240226TT HR P20240226 T HRP20240226 T HR P20240226T HR P20240226 T1 HRP20240226 T1 HR P20240226T1
Authority
HR
Croatia
Prior art keywords
factor
binding protein
modified
binding
protein
Prior art date
Application number
HRP20240226TT
Other languages
English (en)
Croatian (hr)
Inventor
Rachel Exley
Christoph Tang
Susan Lea
Original Assignee
Ip2Ipo Innovations Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ip2Ipo Innovations Limited filed Critical Ip2Ipo Innovations Limited
Publication of HRP20240226T1 publication Critical patent/HRP20240226T1/hr

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/02Bacterial antigens
    • A61K39/095Neisseria
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66Microorganisms or materials therefrom
    • A61K35/74Bacteria
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/02Bacterial antigens
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/04Immunostimulants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
HRP20240226TT 2008-10-25 2009-10-26 Pripravci cjepiva koji sadrže protein vezivanja mutiranog faktora h HRP20240226T1 (hr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0819633.9A GB0819633D0 (en) 2008-10-25 2008-10-25 Composition
EP18209661.0A EP3501534B1 (en) 2008-10-25 2009-10-26 Vaccine compositions comprising a mutated factor h binding protein

Publications (1)

Publication Number Publication Date
HRP20240226T1 true HRP20240226T1 (hr) 2024-05-10

Family

ID=40133849

Family Applications (1)

Application Number Title Priority Date Filing Date
HRP20240226TT HRP20240226T1 (hr) 2008-10-25 2009-10-26 Pripravci cjepiva koji sadrže protein vezivanja mutiranog faktora h

Country Status (23)

Country Link
US (1) US20120052092A1 (enExample)
EP (2) EP3501534B1 (enExample)
JP (2) JP5676458B2 (enExample)
KR (3) KR20170000390A (enExample)
CN (2) CN102245202A (enExample)
AU (1) AU2009306114B2 (enExample)
BR (1) BRPI0919926A2 (enExample)
CA (1) CA2741619A1 (enExample)
CO (1) CO6382140A2 (enExample)
DK (1) DK3501534T5 (enExample)
ES (1) ES2970878T3 (enExample)
FI (1) FI3501534T3 (enExample)
GB (1) GB0819633D0 (enExample)
HR (1) HRP20240226T1 (enExample)
HU (1) HUE065348T2 (enExample)
LT (1) LT3501534T (enExample)
MX (1) MX2011004322A (enExample)
NZ (2) NZ592444A (enExample)
PL (1) PL3501534T3 (enExample)
PT (1) PT3501534T (enExample)
RU (1) RU2559528C2 (enExample)
SI (1) SI3501534T1 (enExample)
WO (1) WO2010046715A1 (enExample)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2261339B1 (en) 1998-05-01 2017-03-22 GlaxoSmithKline Biologicals SA Neisseria meningitidis antigens and compositions
DK2270173T3 (en) 1999-05-19 2016-03-07 Glaxosmithkline Biolog Sa Neisserial combination compositions
DK1801219T3 (en) 1999-10-29 2015-12-07 Glaxosmithkline Biolog Sa Neisseriale antigenic peptides.
EP2270031A3 (en) 2000-02-28 2011-02-16 Novartis Vaccines and Diagnostics S.r.l. Heterologous expression of neisserial proteins
GB0118249D0 (en) 2001-07-26 2001-09-19 Chiron Spa Histidine vaccines
GB0121591D0 (en) 2001-09-06 2001-10-24 Chiron Spa Hybrid and tandem expression of neisserial proteins
AU2003274511B2 (en) 2002-10-11 2009-06-04 Glaxosmithkline Biologicals S.A. Polypeptide-vaccines for broad protection against hypervirulent meningococcal lineages
GB0227346D0 (en) 2002-11-22 2002-12-31 Chiron Spa 741
GB0408977D0 (en) 2004-04-22 2004-05-26 Chiron Srl Immunising against meningococcal serogroup Y using proteins
GB0524066D0 (en) 2005-11-25 2006-01-04 Chiron Srl 741 ii
US9579372B2 (en) 2008-02-21 2017-02-28 Glaxosmithkline Biologicals Sa Meningococcal fHBP polypeptides
EP2265640B1 (en) 2008-03-10 2015-11-04 Children's Hospital & Research Center at Oakland Chimeric factor h binding proteins (fhbp) containing a heterologous b domain and methods of use
BRPI1009828A2 (pt) 2009-03-24 2019-03-12 Novartis Ag adjuvante de proteína de ligação de fator h meningocócica
AU2010242905B2 (en) 2009-04-30 2014-10-23 Children's Hospital & Research Center At Oakland Chimeric factor H binding proteins (fHbp) and methods of use
BR112012010531A2 (pt) * 2009-10-27 2019-09-24 Novartis Ag "polipeptídeos de modificação meningocócica fhbp"
BR112012022669A2 (pt) * 2010-03-10 2017-02-14 Glaxosmithkline Biologicals Sa composição imunogênica, método de tratamento ou prevenção de infecção ou doença, uso de um antígeno, kit, métodos para a fabricação de uma composição imunogênica e para melhorar uma vacina.
BR112012024348B1 (pt) 2010-03-30 2022-11-08 Children's Hospital & Research Center At Oakland Composição imunogênica, seu uso, proteína de ligação ao fator h de ocorrência não natural, e célula bacteriana geneticamente modificada
US10478483B2 (en) 2010-06-25 2019-11-19 Glaxosmithkline Biologicals Sa Combinations of meningococcal factor H binding proteins
CA2861946A1 (en) 2012-02-02 2013-08-08 Novartis Ag Promoters for increased protein expression in meningococcus
RU2644340C2 (ru) 2012-06-14 2018-02-08 Новартис Аг Вакцины для менингококка серогруппы х
HK1205138A1 (en) 2012-07-27 2015-12-11 Institut National De La Santé Et De La Recherche Médicale (Inserm) Cd147 as receptor for pilus-mediated adhesion of meningococci to vascular endothelia
WO2014140562A1 (en) * 2013-03-14 2014-09-18 Isis Innovation Limited Immunogenic composition to neisseria
KR20160034401A (ko) 2013-08-02 2016-03-29 칠드런즈 하스피틀 앤드 리써치 센터 앳 오클랜드 비-천연적으로 발생하는 인자 h 결합 단백질(fhbp) 및 이의 사용 방법
AU2015222121B2 (en) 2014-02-28 2018-01-18 Glaxosmithkline Biologicals Sa Modified meningococcal fHbp polypeptides
CN119613509A (zh) 2014-07-23 2025-03-14 奥克兰儿童医院及研究中心 因子h结合蛋白变体及其使用方法
BR122023020102A2 (pt) * 2014-08-20 2023-12-12 Stichting Sanquin Bloedvoorziening Anticorpos de potenciamento do fator h e seus usos
GB201614687D0 (en) * 2016-08-31 2016-10-12 Univ Oxford Innovation Ltd fHbp scaffold
EP3607967A1 (en) 2018-08-09 2020-02-12 GlaxoSmithKline Biologicals S.A. Modified meningococcal fhbp polypeptides
KR20210119397A (ko) 2018-12-21 2021-10-05 그리피스 유니버시티 면역 반응을 유도하기 위한 조성물, 방법 및 용도
EP3997108A4 (en) * 2019-07-08 2024-03-20 Crapaud Bio, Inc. METHODS OF PRODUCING AND USING LIPOOLIGOSACCHARIDE COMPOSITIONS AND VACCINES
CA3147638A1 (en) 2019-07-17 2021-01-21 Gemini Therapeutics Sub, Inc. Factor h potentiating antibodies and uses thereof
JP2024507828A (ja) 2021-02-19 2024-02-21 サノフィ パスツール インコーポレイテッド B群髄膜炎菌組換えワクチン
TW202423477A (zh) 2022-08-03 2024-06-16 美商賽諾菲巴斯德公司 針對腦膜炎奈瑟氏菌b的含佐劑免疫原性組成物

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4786592A (en) * 1986-06-18 1988-11-22 Scripps Clinic And Research Foundation Neisseria gonorrhoeae lectin useful as a vaccine and diagnostic marker and means for producing this lectin
US5476784A (en) * 1993-04-06 1995-12-19 Rice; Peter A. Gonococcal anti-idiotypic antibodies and methods and compositions using them
GB0220194D0 (en) * 2002-08-30 2002-10-09 Chiron Spa Improved vesicles
US20070253964A1 (en) * 2003-04-16 2007-11-01 Zlotnick Gary W Novel Immunogenic Compositions for the Prevention and Treatment of Meningococcal Disease
US9034345B2 (en) * 2005-01-27 2015-05-19 Children's Hospital & Research Center Oakland GNA1870-based vesicle vaccines for broad spectrum protection against diseases caused by Neisseria meningitidis
GB0524066D0 (en) * 2005-11-25 2006-01-04 Chiron Srl 741 ii
RU2450019C2 (ru) * 2006-06-29 2012-05-10 Новартис Аг Полипептиды из neisseria meningitidis
NZ598458A (en) * 2009-08-27 2014-03-28 Novartis Ag Hybrid polypeptides including meningococcal fhbp sequences
BR112012024348B1 (pt) * 2010-03-30 2022-11-08 Children's Hospital & Research Center At Oakland Composição imunogênica, seu uso, proteína de ligação ao fator h de ocorrência não natural, e célula bacteriana geneticamente modificada

Also Published As

Publication number Publication date
AU2009306114B2 (en) 2015-10-01
EP3501534B1 (en) 2023-11-29
DK3501534T5 (da) 2024-09-02
SI3501534T1 (sl) 2024-03-29
JP2015063558A (ja) 2015-04-09
CN102245202A (zh) 2011-11-16
GB0819633D0 (en) 2008-12-03
EP3501534A1 (en) 2019-06-26
CN105412920A (zh) 2016-03-23
JP6076326B2 (ja) 2017-02-08
KR20110092282A (ko) 2011-08-17
DK3501534T3 (da) 2024-02-05
ES2970878T3 (es) 2024-05-31
WO2010046715A1 (en) 2010-04-29
PL3501534T3 (pl) 2024-04-02
NZ592444A (en) 2012-11-30
KR20170000390A (ko) 2017-01-02
CO6382140A2 (es) 2012-02-15
US20120052092A1 (en) 2012-03-01
LT3501534T (lt) 2024-03-12
PT3501534T (pt) 2024-02-07
JP2012506411A (ja) 2012-03-15
EP2355845B1 (en) 2018-12-05
HUE065348T2 (hu) 2024-05-28
KR20190011836A (ko) 2019-02-07
CA2741619A1 (en) 2010-04-29
EP2355845A1 (en) 2011-08-17
AU2009306114A1 (en) 2010-04-29
FI3501534T3 (fi) 2024-02-09
NZ601538A (en) 2014-01-31
JP5676458B2 (ja) 2015-02-25
RU2559528C2 (ru) 2015-08-10
RU2011120706A (ru) 2012-11-27
MX2011004322A (es) 2011-06-16
BRPI0919926A2 (pt) 2016-02-16

Similar Documents

Publication Publication Date Title
HRP20240226T1 (hr) Pripravci cjepiva koji sadrže protein vezivanja mutiranog faktora h
RU2017104529A (ru) Композиции neisseria meningitidis и способы их применения
JP2016040284A5 (enExample)
JP2012506411A5 (enExample)
WO2008079372A3 (en) Novel immunogenic compositions for the prevention and treatment of meningococcal disease
HRP20161608T1 (hr) Modificirani tuberkulozni antigeni
JP2016509011A5 (enExample)
NZ595063A (en) Polypeptides from neisseria meningitidis
JP2017081939A5 (enExample)
WO2008054540A3 (en) Inducing immune responses to influenza virus using polypeptide and nucleic acid compositions
HRP20220717T1 (hr) Modificirani pripravci mrna
BRPI0212999B1 (pt) novas composições imunogênicas para a prevenção e tratamento de doença meningocócica
EP4272750A3 (en) Protein antigens that provide protection against pneumococcal colonization and/or disease
JP2010011868A5 (enExample)
JP2010215657A5 (enExample)
PE20140173A1 (es) Variantes no lipidadas de antigenos orf2086 de neisseria meningitidis
JP2015514132A5 (enExample)
JP2015513527A5 (enExample)
JP2011517938A5 (enExample)
JP2009520758A5 (enExample)
JP2016520534A5 (enExample)
JP2015529677A5 (enExample)
JP2013542942A5 (enExample)
HRP20180039T1 (hr) Antigeni pseudomonasa i kombinacije antigena
NZ591738A (en) Non-typhoidal salmonella vaccines comprising a polypeptide which is an outer membrane protein d of non typoidal salmonella